Coherus Reports the US FDA’s Acceptance of BLA for CHS-1420 (biosimilar, adalimumab)

February 18, 2021 Auto Bot Biosimilar, Biosimilars, BLA, Coherus, Review, Us FDA 0

Shots:

  • The US FDA has accepted the BLA under the 351(k) for CHS-1420 with an anticipated BsUFA date as Dec’2021
  • The company plans to launch the CHS-1420 in the US on or after Jul 01, 2023 as per the terms of an agreement with AbbVie
  • Coherus collaborated with Junshi in Feb’2021 to in-license toripalimab in the US and Canada. Additionally, Coherus will market Udenyca (pegfilgrastim) in the US and plans to launch biosimilars of Humira, Avastin and Lucentis in 2023, following their approval

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Coherus

The post Coherus Reports the US FDA’s Acceptance of BLA for CHS-1420 (biosimilar, adalimumab) first appeared on PharmaShots.